WellMed CEO George M. Rapier, III, M.D. Joins Board of Directors of Potrero Medical

SAN FRANCISCO, Feb. 11, 2016 /PRNewswire/ — Potrero Medical, Inc., the developer of the Accuryn™ critical care monitoring system, is pleased to announce the appointment of George M. Rapier, III, MD, to its Board of Directors.

Dr. Rapier is a distinguished clinician, entrepreneur and philanthropist who serves as Chairman and CEO of WellMed Medical Management, Inc.  Headquartered in San Antonio, TX, WellMed is one of the nation’s largest physician owned practice management companies, servicing over 200,000 patients and HMO members in Texas and Florida.    Since founding WellMed in 1990 out of his own internal medicine practice, he has been instrumental to the company’s growth into a multi-billion dollar business focused on continuously improving patient care.  Dr. Rapier developed and has continued to work with specialists to implement disease management programs to enhance the quality of life for WellMed patients.   He led the development of clinical health protocol screening systems to access and evaluate clinical, lab and medication data, assisting in providing preventive health and screening recommendations to physicians, and was a pioneer in the implementation of electronic health records. In September 2009 Modern Physician Magazine named Dr. Rapier Physician Entrepreneur of The Year.    Through the Rapier Charitable Trust and the WellMed Charitable Foundation, Dr. Rapier and his wife, Kym, have provided millions of dollars in grants to support educational, health, and social welfare causes in the San Antonio, TX area.

“Potrero Medical’s technology presents an exciting new opportunity to improve outcomes and lower the cost of care for a wide range of critically ill patients.  I am excited to join with management to put this potentially life-saving technology into the hands of care-givers worldwide,” said Dr. Rapier.

Daniel Burnett, MD, Founder and CEO of Potrero Medical stated, “Dr. Rapier is a tremendous addition to our Board of Directors. We expect to benefit greatly both from his deep understanding of care delivery for the patient populations that we are targeting and his experience in introducing impactful new technologies.”

About the Accuryn™ System:

Accuryn™ is a critical care monitoring system that transforms the traditional urinary catheter into a next-generation diagnostic tool.  Accuryn uses proprietary electromechanical designs and advanced software algorithms to deliver automated, real-time actionable data including urine output, core temperature and intraabdominal pressure.

Potrero Medical, Inc. has demonstrated superiority of Accuryn™ in a multi-center randomized clinical study of Accuryn™ against the current gold standard device. The company is currently engaged in a multi-center study of Accuryn™ to detect sepsis and critical illness (PRESCIENT), which is projected to enroll up to 100 patients in the United States.

The Accuryn™ System is currently an investigational medical device and is not for sale in the United States.

About Potrero Medical, Inc.:

Potrero Medical, Inc., the latest spinout of medical device incubator Theranova, LLC, is headquartered in San Francisco, CA and was founded with a mission to improve outcomes, reduce costs and expand access to healthcare. For more information about the company, please visit www.potreromed.com

Potrero Medical Commences NIH-backed PRESCIENT Study of Accuryn™ For Early Detection of Critical Illness

SAN FRANCISCO, Feb. 2, 2016 /PRNewswire/ — Potrero Medical, Inc. today announced the start of the PRESCIENT study, an NIH-sponsored, multi-center observational study using the Accuryn™ Monitoring System to detect the physiological signatures of critical illnesses, including sepsis.

Professor Raul Coimbra, MD, the lead investigator for the study and Chief of the Division of Trauma Surgery at the University of California San Diego, Hillcrest, stated, “We are excited to have enrolled our first patient in the PRESCIENT study which will contribute significantly to the understanding of the physiologic signatures of a variety of critical illnesses in the ICU.  This understanding may ultimately lead to earlier detection, and possibly even prediction, of these highly morbid and costly illnesses.”

“This study is intended to test the Accuryn system as a potential new tool for patient monitoring and treatment in the ICU.  The device has the potential to provide an early indication of sepsis and, perhaps more importantly, future studies of the additional capabilities of this device could lead to actionable data in guiding resuscitation,” said Phillip Dellinger, MD, Chief of Medicine at Cooper University Health Care in Camden, NJ and Clinical Advisor to Potrero Medical.

Daniel Burnett, MD, Founder and CEO of Potrero Medical stated, “Initiation of this study is another important milestone for us and another step on the path to creating what we believe will be a new gold standard diagnostic platform for the detection and treatment of critical illness.  We are thrilled to have the support of Dr. Coimbra, Dr. Dellinger and other leaders in critical care who share our vision for Accuryn™ as a potentially life-saving and cost-saving solution.”

Potrero Medical was awarded $2.25M in SBIR grants from the NIH’s National Institute of General Medical Sciences to run the multi-center PRESCIENT study which is projected to enroll up to 100 patients in the United States.

About the Accuryn™ System:

Accuryn™ is a critical care monitoring system that transforms the traditional urinary catheter into a next-generation diagnostic tool.  Accuryn uses proprietary electromechanical designs and advanced software algorithms to deliver automated, real-time actionable data including urine output, core temperature and intraabdominal pressure.

Potrero Medical Inc. previously demonstrated superiority of Accuryn™ in a multi-center randomized clinical study of Accuryn™ against the current gold standard device.  The Accuryn™ System is currently an investigational medical device and is not for sale in the United States.

About Potrero Medical, Inc.:

Potrero Medical, Inc., the latest spinout of medical device incubator Theranova, LLC, is headquartered in San Francisco, CA and was founded with a mission is to improve outcomes, reduce costs and expand access to healthcare. For more information about the company, please visit www.potreromed.com.